Mismatch repair endometrial cancer, what to do at first recurrence and beyond?-Recording

Video Transcription

Video Summary

In this video, Dr. Flora Backus and Dr. Ramez Iskander discuss the treatment of mismatch repair-deficient recurrent endometrial cancer. They focus on the addition of immunotherapy to chemotherapy and its impact on patient outcomes. They discuss several clinical trials that have shown a significant improvement in progression-free survival when immunotherapy is added to chemotherapy in this patient population. They also talk about the differences between patients with hypermethylated MLH1 and those with somatic mutations or lynch-like patients. They highlight the need for further research to better understand the impact of race and ethnicity on treatment efficacy. Additionally, they discuss treatment options for patients who have completed maintenance immunotherapy and experience a recurrence, emphasizing the importance of clinical trials for these patients. Overall, the discussion highlights the evolving treatment landscape for recurrent endometrial cancer and the need for personalized approaches based on individual patient characteristics.

Keywords

treatment

mismatch repair-deficient

recurrent endometrial cancer

immunotherapy

chemotherapy

patient outcomes